scPharmaceuticals to Present at the Jefferies Global Healthcare Conference
May 29, 2024 16:01 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024 16:01 ET
|
scPharmaceuticals, Inc.
Generated 1Q 2024 net FUROSCIX® revenue of $6.1 million, despite an estimated 10% impact to doses filled resulting from the Change Healthcare cyberattack Ended 1Q 2024 with cash and cash equivalents...
scPharmaceuticals to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 13, 2024 16:05 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals to Announce First Quarter 2024 Financial Results on Tuesday, May 14, 2024
May 07, 2024 16:05 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection
April 24, 2024 08:00 ET
|
scPharmaceuticals, Inc.
FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor Company anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end...
scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
March 13, 2024 16:01 ET
|
scPharmaceuticals, Inc.
Generated 4Q 2023 net FUROSCIX® revenue of $6.1 million, at the upper end of the range provided in January and representing sequential growth of 61% from $3.8 million in 3Q 2023 Generated full-year...
scPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024
March 06, 2024 16:01 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals to Participate in Two Upcoming Investor Conferences
February 28, 2024 16:01 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue
January 04, 2024 16:05 ET
|
scPharmaceuticals, Inc.
Company anticipates Q4 2023 net FUROSCIX revenue to be approximately $5.9 to $6.1 million; full-year net FUROSCIX revenue of approximately $13.4 to $13.6 million Gross-to-net (GTN) discount of...
scPharmaceuticals Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update
November 08, 2023 16:01 ET
|
scPharmaceuticals, Inc.
Generated net FUROSCIX® revenue of $3.8 million Ended Q3 2023 with cash, cash equivalents and short-term investments of $90.2 million Company to host investor conference call and webcast today,...